Less increase of copeptin and MR-proADM due to intervention with selenium and coenzyme Q10 combined: Results from a 4-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens.

Urban Alehagen, Jan Aaseth and Peter Johansson

Linköping University Post Print

N.B.: When citing this work, cite the original article.

Original Publication:
Urban Alehagen, Jan Aaseth and Peter Johansson, Less increase of copeptin and MR-proADM due to intervention with selenium and coenzyme Q10 combined: Results from a 4-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens., 2015, Biofactors, (41), 6, 443-452.
http://dx.doi.org/10.1002/biof.1245
Copyright: IOS Press / Wiley
http://eu.wiley.com/WileyCDA/
Postprint available at: Linköping University Electronic Press
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-124294
Less increase of Copeptin and MR-proADM due to intervention with selenium and coenzyme Q10 combined. Results from a four-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens.

Urban Alehagen 1*, Jan Aaseth 2 and Peter Johansson 3

1 :Department of Cardiology and, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. E-mail address: urban.alehagen@liu.se

2 :Research Department, Innlandet Hospital Trust and Hedmark University College, Norway. E-mail address: jaol-aas@online.no

3 : Department of Cardiology and, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. E-mail address: peter.johansson@aries.vokby.se

Running title: copeptin and MR-proADM reduced by selenium and coenzyme Q10
Intervention with selenium and coenzyme Q10 have recently been found to reduce mortality and increase cardiac function. The mechanisms behind these effects are unclear. As selenium and coenzyme Q10 is involved in the anti-oxidative defence, the present study aimed to evaluate effects of selenium and coenzyme Q10 on copeptin and adrenomedullin as oxidative stress biomarkers.

Therefore 437 elderly individuals were included and given intervention for 4 years. Clinical examination and blood samples were undertaken at start and after 18 and 48 months. Evaluations of copeptin and MR-proADM changes were performed using
repeated measures of variance. Cardiovascular mortality was evaluated using a 10-
year-period of follow-up, and presented in Kaplan-Meier plots.

A significant increase in copeptin level could be seen in the placebo group during the
intervention period (from 9.4 pmol/L to 15.3 pmol/L), compared to the active
treatment group. The difference between the groups was confirmed in the repeated
measurement of variance analyses ($P=0.031$) with less copeptin increase in the
active treatment group. Furthermore, active treatment appeared to protect against
cardiovascular death both in those with high and with low copeptin levels at inclusion.

Less increase of MR-proADM could also be seen during the intervention in the active
treatment group compared to controls ($P=0.026$). Both in those having an MR-
proADM level above or below median level, significantly less cardiovascular mortality
could be seen in the active treatment group ($P=0.0001$, and $P=0.04$ respectively).

In conclusion supplementation with selenium and coenzyme Q10 during four years
resulted in less concentration of both copeptin and MR-proADM. A cardioprotective
effect of the supplementation was registered, irrespective of the initial levels of these
biomarkers, and this protection was recognized also after 10 years of observation.

The main study was registered at Clinicaltrials.gov, and has the identifier
NCT01443780.

BACKGROUND
We have previously reported on the effect of dietary supplementation of selenium and coenzyme Q10 on an elderly community population in Sweden [1]. The supplementation resulted in improved cardiac function as assessed by echocardiography and decreased cardiovascular mortality, as compared to the controls. To the authors' knowledge, no other reports using this combined intervention are found in the literature, with the exception of a small study on patients with acute myocardial infarction [2]. There are reports on positive effects of intervention with coenzyme Q10, as can be seen in the QSYMBIO study [3]. With regard to selenium, Rees et al. published a Cochrane report indicating no effect of the supplementation on mortality [4]. But, as the authors state, 95% of their included patients originated from the SELECT or the NPC trials, thus essentially involving US populations, which have relatively high basic selenium intake, with estimated mean selenium intake of 134 µg/day in males and 93 µg/day in females [5]. This is substantially higher than European levels [6]. Thus, the need for supplementation in US populations could be questioned, and this could also provide an explanation for inconsistent results of selenium supplementation.

Selenium, one of the trace elements, is essential for all living cells [7, 8]. It is mostly found as selenoproteins in the body, including glutathione peroxidases, thioredoxin reductase and selenoprotein P, which protects against oxidative stress [9]. However, selenium is also important in the inflammatory response in different disease states [10], and increased vascular oxidative stress and endothelial dysfunction have been reported to characterize patients with coronary heart disease [11, 12]. An important interrelationship between selenium and coenzyme Q10 (ubiquinone) is the catalytic role of selenoproteins in the metabolic conversion of ubiquinone to ubiquinol, the active form of coenzyme Q10 [11]. Furthermore, the
presence of coenzyme Q10 is needed for the optimal synthesis of selenocysteine-containing enzymes [13, 14]. Reduced coenzyme Q10 (ubiquinol) is an important antioxidant, effectively protecting against lipid peroxidation [15, 16], and it also reduces inflammatory response [17], also in those with diabetes [18]. However, the endogenous synthesis of coenzyme Q10 decreases after the age of 20, and the myocardial production is reduced to half at the age of 80 years [19]. Thus, elderly people living in geographical areas with low selenium content in the soil and food may have reduced protection against oxidative stress. Thus, restoration of the antioxidative capacity by supplementation with selenium and coenzyme Q10 could be one of the underlying mechanisms behind our previously reported positive results [1].

The biomarker vasopressin (AVP) is released from the neurohypophysis in response to different types of stressors, including oxidative stress but also in response to changes in plasma osmolality. AVP is involved in osmoregulation and cardiovascular homeostasis. The plasma concentration of AVP increases in patients with heart failure, and especially in response to left ventricular dysfunction [20]. However, as AVP is degraded rapidly in the circulation, it is not a useful plasma biomarker in clinical settings. Instead, copeptin, the C-terminal fragment of pro-vasopressin, has emerged as a promising surrogate marker for the AVP response, and copeptin measurements have also been shown to be useful in the handling of patients with cardiovascular disease [21-24]. A special emphasize on the association between copeptin and cardiovascular mortality in different conditions should be mentioned [25-28].
Adrenomedullin (ADM), another promising biomarker, possesses vasoactive properties [29] and appears to reflect and counteract oxidative stress, as shown in a mice model by Shimosawa et al. [30]. Thus high levels of adrenomedullin may indicate substantial oxidative stress. PreproADM is the precursor of ADM, and in addition to ADM itself, the mid-regional part of this precursor (MR-proADM) is released to the circulation [31]. As measuring ADM in plasma has proven to be difficult owing to its rapid attachment to the binding protein, complement factor H, and its short half-life in the circulation, MR-proADM measurement acts as a reliable ADM surrogate marker in the circulation, and is easier to monitor.

Supplementation with selenium and coenzyme Q10 has the potential to protect against oxidative stress. Theoretically, this should decrease or stabilize the levels of copeptin and MR-proADM.

The present study report that the concentrations of copeptin and MR-proADM decreases or stabilizes as a result of the intervention. Secondly, the project could present a reduced cardiovascular mortality in the active intervention group, irrespective of the levels of the two biomarkers also after a 10 years of follow-up.

METHODS

Study population

This is a secondary analysis of a prospective randomized double-blind placebo-controlled trial in an elderly community population of 443 individuals with an age
range of 70-88 years. The trial has been previously reported [1, 32]. All participants received the intervention for 48 months, during which they were re-examined every six months. In the study, 221 individuals received active supplementation of 200 μg/day organic selenium (SelenoPrecise®, Pharma Nord, Denmark), plus 200 mg/day of coenzyme Q₁₀ (Bio-Quinon®, Pharma Nord, Denmark), and 222 individuals received a placebo. At inclusion, all participants went through a clinical examination, new patient records were obtained, the New York Heart Association functional class was assessed, and an ECG and Doppler-echocardiography were performed. Informed consent was obtained from each patient. All participants gave their informed consent. The study was approved by the Regional Ethical Committee (diary number 03-176) and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. (The Medical Product Agency declined to review the study protocol since the study was not considered a trial of a medication for a certain disease but rather one of food supplement commodities that are commercially available).

All mortality was registered, and followed until 10 years after the end of the study.

Blood samples

Blood samples were collected while the participants were resting in a supine position. Pre-chilled, EDTA vials were used. The vials were centrifuged at 3000g, +4°C, and were then frozen at -70°C. No sample was thawed more than once.

NT-proBNP and copeptin analyses
ProBNP 1-76 (NT-proBNP) was measured on the Elecsys 2010 platform (Roche Diagnostics, Mannheim, Germany). Total CV was 4.8% at 26 pmol/L and 2.1% at 503 pmol/L. Plasma copeptin was measured on the Kryptor Compact platform (BRAHMS Gmbh, Hennigsdorf, Germany). The interassay CVs were <15% at 20 pmol/L, <13% for 20-50 pmol/L, and <8 pmol/L for concentrations >50 pmol/L according to previous validation [33] and information from the manufacturer[33].

**MR-proADM**

MR-proADM was analyzed with the use of a commercially available assay on the Kryptor platform (BRAHMS Gmbh, Hennigsdorf, Germany) [31]. The interassay coefficient of variation was <20% for samples from 0.2 to 0.5 nmol/L, <11% for samples from 0.5 to 2 nmol/L, and <10% for samples from 2 to 6 nmol/L.

**Statistics**

Descriptive data are presented as percentages or mean ± SD. The Student’s unpaired two-sided T-test was used for continuous variables. Evaluation of the effects of treatment was based on the group mean, but the values of the individual participant were identified during three different measured time points (baseline, 18, and 48 months) using a repeated measures of variance analysis. Kaplan-Meier plots of cardiovascular mortality for the period of up to 10 years were made separately for copeptin and MR-proADM, each divided in two at their median levels. The term ‘censored participants’ refers to those still living at the end of the study, or who had died for reasons other than cardiovascular disease. ‘Completed participants’ refer to
those who died due to cardiovascular disease. Evaluation of the $P$-values of mortality differences between the two groups was based on lifetable analyses using cumulative proportion surviving, and the standard error of cumulated survival to obtain a z-value. Cox proportional hazard regression analysis was used to evaluate the risk of cardiovascular mortality where a follow-up period of up to 10 years was applied. The independent variables included in the multivariate model were variables known to be associated with CV mortality: age, male gender, smoking, hyperlipidemia, diabetes, Hb<120g/L, obstructive pulmonary disease, hypertension, ischemic heart disease, ejection fraction (EF)<40%, ACE-inhibitor treatment, and treatment with diuretics. $P$-values < 0.05 were considered significant, based on a two-sided evaluation. All data were analysed using standard software (Statistica v. 12.0, Statsoft Inc, Tulsa, OK, USA.).

RESULTS

The baseline characteristics of the study population are presented in Table 1, and a CONSORT flow chart of the study is presented in Fig.1. The follow-up period in the main publication was 1900 days, as indicated in Fig.1. It can be seen that the final population consisted of 437 individuals, as samples for evaluation of MR-proADM and copeptin were not present in six of the 443 individuals primarily included. Of the total population, 216 individuals in the active supplementation group, and 221 in the placebo group were evaluated. The mean age at the start of the intervention was approximately 77 years, and the size of the male
and female fractions were practically equal in the groups. The active treatment group and placebo group were well balanced in all baseline variables (Table 1), except that the placebo group had a larger proportion receiving treatment with ACE-inhibitors (24% vs. 15%; \( P=0.02 \)). No differences could be seen regarding history of diabetes or ischemic heart disease between the two groups.

At inclusion, the concentrations of NT-proBNP were almost equal in the two groups (537 ng/L vs. 516 ng/L). These mean concentrations were not as high as in patients with overt heart failure [34]. At the study start, about 7% in both groups had impaired heart function, here defined as EF<40%, according to echocardiography. The distribution of the different quartiles of plasma concentration of the two biomarkers in the different EF classes according to echocardiography are presented in Table 2.

**Copeptin and intervention with selenium and coenzyme Q10 combined**

At the study start no difference in copeptin concentrations was seen between the actively treated and the placebo group (\( P=0.45 \)). The mean concentration of copeptin in the active treatment group at the start was 10.7 pmol/L (SD 9.4), and at the end of the study it was 10.9 pmol/L (SD 7.2). Thus, no significant difference between the start and the end based on group mean concentration could be found in the supplemented group (\( P=0.87 \)). In the placebo group the copeptin concentration was 9.4 pmol/L (SD 7.4) at the start, and 15.3 pmol/L (SD 15.3) at the end of the study. Thus, a significant increase in copeptin concentration occurred in the placebo group between the start and end of the study (\( P=0.001 \)).
To further explore the possible treatment effect a repeated measures of variance was performed. This evaluation showed a significant treatment effect on the copeptin level \((F=4.85; \, P=0.009)\), indicating that a significant difference between active intervention and placebo existed. Evaluation of the interaction revealed a significant interaction \((F= 3.54; \, P=0.03)\) indicating that the obtained treatment effect was not based on differences in the copeptin levels of the two groups at the start, but to a significantly reduced level of copeptin due to the intervention (Fig. 2).

Cardiovascular mortality was monitored during 10 years of follow-up. In this evaluation the initial plasma concentrations of copeptin were divided into two groups; above versus below the median concentration. The cardiovascular mortality during the follow-up period in those with a plasma concentration of copeptin above the median is presented in Fig. 3a, and those with a plasma concentration below the median is presented in Fig. 3b. From these evaluations a significantly decreased cardiovascular mortality \((\chi^2: 10.20; \, P=0.0014)\) could be demonstrated in those on active treatment and with a copeptin level above the median level, compared to the controls, applying a 10-year follow-up period. Also, in those with a copeptin concentration below the median at the study start, a significantly decreased cardiovascular mortality could be demonstrated in those on active supplementation, compared to the controls \((\chi^2: 8.47; \, P=0.0036)\).

In an overall risk evaluation of the cardiovascular mortality of those on active supplementation versus placebo, the risk reduction attributed to the present intervention was between 39 and 41 %, as seen in the multivariate model including established clinical variables influencing the risk, if copeptin at the start of the intervention was below, versus above the median concentration, when applying a follow-up time of 10 years (Table 3).
MR-proADM and intervention with selenium and coenzyme Q10 combined

The levels of MR-proADM showed a plasma concentration of 721 pmol/L (SD 143) in the actively treated group at the study start, and 754 pmol/L (SD 203) at the study end, thus no significant change occurred during the treatment course. In the placebo group the plasma concentration of MR-proADM at the study start was 760 pmol/L (SD 169), and at the end it was 865 pmol/L (SD 241); thus, there was a significant increase of the mean level of MR-proADM ($p=0.01$).

Performing the same procedure as described above, to evaluate a possible treatment effect of selenium and coenzyme Q10 on the MR-proADM level, showed a significant treatment effect ($F=10.78; P<0.0001$), and a significant interaction ($F=3.70; P=0.03$). Thus, a significant treatment effect was seen on the MR-proADM level (Fig. 4).

On evaluation of cardiovascular mortality during 10 years of follow-up the plasma concentrations of MR-proADM were divided into two subgroups, above versus below the median level. The cardiovascular mortality during the follow-up period in those with a plasma concentration of MR-proADM above the median is presented in Figure 5a. It was found that in those with an MR-proADM concentration at the study start above median, active supplementation resulted in significantly less cardiovascular mortality than in the controls, as registered during a follow-up period of 10 years ($\chi^2: 14.56; P=0.0001$). Significantly reduced cardiovascular mortality in the actively treated group compared to the controls was also seen in those with an MR-proADM concentration below the median at study start ($\chi^2: 4.19; P=0.0406$)(Fig. 5b).

The overall risk of cardiovascular mortality when applying a 10 year follow-up period was also evaluated as an effect of active intervention compared to placebo in those
having a MR-proADM concentration above versus below the median concentration (Table 3). A risk reduction of between 54 to 40% could be seen in the two groups as applied in a multivariate model including clinical variables influencing the risk of cardiovascular mortality.

DISCUSSION

The present report demonstrates the effect of dietary supplementation with selenium and coenzyme Q10 on the plasma concentration of the two biomarkers copeptin and MR-proADM, indicating a possible protection against oxidative stress by the intervention. Both copeptin and MR-proADM has in the literature been shown to exhibit prognostic information, especially regarding patients with heart failure [25, 35-39]. However, there are also reports that there is an association between plasma concentration between the biomarkers and cardiac function, even if this association does not seem to be strong [40]. We have presented the distribution of the two biomarkers in the different quartiles in the different cardiac systolic function classes in Table 2, and there is a trend towards higher concentration of the biomarkers as the cardiac function decreases. However, as the study population consisted of retired community members from a rural municipality, the part with decreased cardiac function is small, influencing the interpretation of the Table 2.

The combination of selenium and coenzyme Q10 may result in an enhanced antioxidative action [14]. As the selenium intake in Sweden is low or suboptimal [6], the supplementation is presumed to optimize the function of several selenoenzymes
including the enzymatic conversion of coenzyme Q10 to its active form, ubiquinol [13]. We combined the selenium supplementation with coenzyme Q10 [41] because coenzyme Q10 apparently has positive effects on cellular oxidative stress, as seen in patients with coronary artery disease [42]. As the need for coenzyme Q10 increases during conditions of increased oxidative stress, and inflammation, as well as with increased age, there may be a need for supplementation of coenzyme Q10 in elderly patient categories, such as in the present population under investigation.

In the actively supplemented group the circulating levels of these two biomarkers did not increase significantly during the treatment course of four years, in contrast to their values in the controls, which exhibited a continuous and substantial increase. In the literature there are data indicating that a higher level of oxidative stress results in a higher level of vasopressin, and thus also of copeptin [43]. However, there is little information regarding the expected increase due to age in an elderly healthy community population in the literature. In a sub-study to the OPTIMAAL study including patients with heart failure after myocardial infarction, Voors et al. showed a relation where in the fourth quartile of copeptin concentration a higher mean age could be found compared to those in the first quartile of copeptin concentration [23]. Our population consisted of elderly persons and might also have included individuals with various early stages of different diseases. This could explain the relatively high mean level of copeptin concentration at the study start, and the increased level at the study end in those on placebo.

With regard to MR-proADM, a similar difference appeared between the supplemented and the control groups as described above for copeptin. The levels of MR-proADM increase in the circulation with age [44]. However, according to a report from Morgenthaler et al. the mean values in healthy persons were lower than our
values, even though their sample size in the corresponding age group was small [31].

Again, this could mean that part of the present population had disease states that
influenced the mean values. However, the important observation is the effect of the
intervention, where a significantly smaller increase could be seen in those given
supplementation compared to the controls.

Adrenomedullin has previously been shown to protect the cardiovascular system
against oxidative stress [45, 46]. It is a reasonable hypothesis that the reductions in
MR-proADM as well as in copeptin levels indicate that a lower level of oxidative
stress was obtained by the intervention with selenium and coenzyme Q10, although
other mechanisms of action may also have been involved.

Our hypothesis is strengthened by the analysis of cardiovascular mortality, as
presented earlier [1]. We observed significantly less cardiovascular mortality in those
on supplementation with selenium and coenzyme Q10 compared to placebo, and the
reducing effect on cardiovascular mortality appeared to persist throughout the
observation period of 10 years. The mechanism behind this long-lasting protection
remains a matter of speculation. The four-year-period on supplementation may have
prevented the development of irreversible or structural changes in the cardial
vasculature. However, this has to be further investigated.

LIMITATIONS

The studied population was of limited size, 437 individuals, which makes the
interpretation of the results difficult. However, as the difference between the two
groups, active supplementation versus placebo, was highly significant, it is probable
that the results reflect real changes. The report should be regarded as a hypothesis-
generating study, and as such it has interesting information that could be used in further research.

The study population was not included through a sampling process, but invited because they were living in the same rural community. This could result in a bias, resulting in a lower threshold of participation among those with known or unknown diseases, and impaired well-being hoping for a diagnosis or medical treatment adjustment. This could result in even higher levels of the two biomarkers compared to other healthy populations of corresponding age. However, the total study population was randomized into two groups, and therefore a similar health situation could be expected in those given active treatment and those on placebo. In this report only two biomarkers that are involved in a multitude of processes in the body are evaluated.

The two biomarkers monitored in this study, copeptin and MR-proADM, may reflect pathology in different locations in the body [47] and they may be influenced by various pathological processes, including cardiovascular diseases [47]. Therefore, other analyses could have been performed retrospectively that may be more specific for oxidative stress. However, the results indicating an effect on different processes by the intervention are significant as reflected by the size of the difference between those on active supplementation versus placebo, which is why the choice of the two biomarkers could be argued as reasonable.

CONCLUSION

The concentration of the biomarkers copeptin and MR-proADM reflects the intensity of oxidative stress in the body, although they may be influenced by other processes.
Recently, data on intervention with selenium and coenzyme Q10 were presented, showing they provide significant protection for cardiac function and against cardiovascular mortality in an elderly population in Sweden. In the present study, the two biomarkers copeptin and MR-proADM did not exhibit an increase in the actively treated group compared to the placebo group. Irrespective of whether the initial levels of these biomarkers as indicators of oxidative stress were high or low, supplementation with selenium and coenzyme Q10 exerted protection against cardiovascular mortality also after 10 years of observation. The data support a hypothesis of an anti-oxidative effect of selenium and coenzyme Q10. However, the size of the sample in this study was small and thus more research in the area is needed.

Legends to figures

Figure 1. CONSORT diagram illustrating a flow chart of the study

Figure 2. Presentation of plasma concentration of copeptin at study start, after 18 months, and after 48 months in the two groups with active treatment supplementation and placebo evaluated according to the repeated measure of variance principle.

Figure 3a. Kaplan-Meier graph illustrating cardiovascular mortality in the group with a copeptin concentration above median in those with active treatment versus placebo during a follow-up period of ten years.
Figure 3b. Kaplan-Meier graph illustrating cardiovascular mortality in the group with a copeptin concentration below median in those with active treatment versus placebo during a follow-up period of ten years.

Figure 4. Presentation of plasma concentration of MR-proADM at study start, after 18 months, and after 48 months in the two groups with active treatment supplementation and placebo evaluated according to the repeated measure of variance principle.

Figure 5a. Kaplan-Meier graph illustrating cardiovascular mortality in the group with an MR-proADM concentration below median in those with active treatment versus placebo during a follow-up period of ten years.

Figure 5b. Kaplan-Meier graph illustrating cardiovascular mortality in the group with an MR-proADM concentration above median in those with active treatment versus placebo during a follow-up period of ten years.

**Conflict of interest**

The authors declare no conflict of interest.

**Author contributions**

Dr Alehagen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Alehagen, Aaseth, Johansson.

Acquisition of data: Alehagen, Johansson.

Analysis and interpretation of data: Alehagen, Johansson.
Drafting of the manuscript: Alehagen, Johansson, Aaseth.

Critical revision of the manuscript: Alehagen, Aaseth, Johansson.

Statistical analysis: Alehagen.

Obtained funding: Alehagen.

Study supervision: Alehagen, Aaseth, Johansson.

Part of the analysis costs was supported by grants from Pharma Nord Aps, Denmark, the County Council of Östergötland, Linköping University (UA,PJ).

The funding organizations had no role in the design, management, analysis, interpretation of the data, preparation, review or approval of the manuscript.


34. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2012, 14(8):803-869.


Table 1. Baseline characteristics of the study population receiving intervention of a dietary supplementation of selenium and coenzyme Q10 combined during 4 years.

<table>
<thead>
<tr>
<th></th>
<th>Active</th>
<th>Placebo</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>216</td>
<td>221</td>
<td></td>
</tr>
<tr>
<td>Age years mean (SD)</td>
<td>76.9 (3.5)</td>
<td>77.3 (3.4)</td>
<td>0.35</td>
</tr>
<tr>
<td>Males/Females n</td>
<td>112/104</td>
<td>110/111</td>
<td></td>
</tr>
<tr>
<td><strong>History</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes n (%)</td>
<td>46 (21.3)</td>
<td>48 (21.7)</td>
<td>0.91</td>
</tr>
<tr>
<td>Hypertension n (%)</td>
<td>155 (71.8)</td>
<td>168 (76.0)</td>
<td>0.31</td>
</tr>
<tr>
<td>Obstr. pulm disease n (%)</td>
<td>21 (9.7)</td>
<td>35 (15.8)</td>
<td>0.06</td>
</tr>
<tr>
<td>IHD n (%)</td>
<td>45 (20.8)</td>
<td>52 (23.5)</td>
<td>0.50</td>
</tr>
<tr>
<td>NYHA class I n (%)</td>
<td>117 (54.2)</td>
<td>107 (48.4)</td>
<td>0.23</td>
</tr>
<tr>
<td>NYHA class II n (%)</td>
<td>58 (26.9)</td>
<td>64 (29.0)</td>
<td>0.62</td>
</tr>
<tr>
<td>NYHA class III n (%)</td>
<td>40 (18.5)</td>
<td>47 (21.3)</td>
<td>0.47</td>
</tr>
<tr>
<td>NYHA class IV n (%)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Medications</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin n (%)</td>
<td>58 (26.9)</td>
<td>66 (29.9)</td>
<td>0.48</td>
</tr>
<tr>
<td>Anticoagulants n (%)</td>
<td>26 (12.0)</td>
<td>34 (15.4)</td>
<td>0.31</td>
</tr>
<tr>
<td>ACEI n (%)</td>
<td>32 (14.8)</td>
<td>53 (24.0)</td>
<td>0.02</td>
</tr>
<tr>
<td>ARB n (%)</td>
<td>10 (4.6)</td>
<td>13 (5.9)</td>
<td>0.56</td>
</tr>
<tr>
<td>Beta blockers n (%)</td>
<td>75 (34.7)</td>
<td>72 (32.6)</td>
<td>0.64</td>
</tr>
<tr>
<td>Beta2 stimulants n (%)</td>
<td>20 (9.3)</td>
<td>27 (12.2)</td>
<td>0.32</td>
</tr>
<tr>
<td>Digitalis n (%)</td>
<td>10 (4.6)</td>
<td>11 (5.0)</td>
<td>0.87</td>
</tr>
<tr>
<td>Diuretics n (%)</td>
<td>68 (31.5)</td>
<td>88 (39.8)</td>
<td>0.07</td>
</tr>
<tr>
<td>Statins n (%)</td>
<td>42 (19.4)</td>
<td>50 (22.6)</td>
<td>0.41</td>
</tr>
<tr>
<td>Examination</td>
<td>Value 1</td>
<td>Value 2</td>
<td>p-value</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>EF&lt;40% n (%)</td>
<td>14 (6.5)</td>
<td>17 (7.7)</td>
<td>0.65</td>
</tr>
<tr>
<td>Atrial fibrillation n (%)</td>
<td>21 (9.7)</td>
<td>20 (9.0)</td>
<td>0.81</td>
</tr>
<tr>
<td>NT-proBNP ng/L mean (IQR)</td>
<td>537 (398)</td>
<td>516 (330)</td>
<td>0.86</td>
</tr>
<tr>
<td>Copeptin pmol/L mean (IQR)</td>
<td>10.7 (12.0)</td>
<td>9.4 (6.6)</td>
<td>0.45</td>
</tr>
<tr>
<td>MR-proADM pmol/L mean (IQR)</td>
<td>721 (161)</td>
<td>760 (254)</td>
<td>0.20</td>
</tr>
</tbody>
</table>

Note: ACEI: ACE- inhibitors; ARB; Angiotension receptor blockers; EF: Ejection fraction; IHD; Ischemic heart disease; IQR: Inter quartile range; NT-proBNP: N-terminal fragment of proBNP; NYHA: New York Heart Association functional class; SD: Standard Deviation.
Table 2a. Distribution of ejection fraction into the four quartiles of copeptin

<table>
<thead>
<tr>
<th>Quartile</th>
<th>EF&lt;30%</th>
<th>EF 30-40%</th>
<th>EF 31-50%</th>
<th>EF&gt;50%</th>
<th>Unclassified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1, n (%)</td>
<td>1 (0.9)</td>
<td>1 (0.9)</td>
<td>6 (5.6)</td>
<td>100 (92.6)</td>
<td>0</td>
</tr>
<tr>
<td>Q2, n (%)</td>
<td>0</td>
<td>4 (3.7)</td>
<td>8 (7.3)</td>
<td>97 (89.0)</td>
<td>0</td>
</tr>
<tr>
<td>Q3, n (%)</td>
<td>3 (2.8)</td>
<td>9 (8.5)</td>
<td>17 (16.0)</td>
<td>76 (71.7)</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td>Q4, n (%)</td>
<td>3 (2.7)</td>
<td>11 (9.9)</td>
<td>20 (18.0)</td>
<td>75 (67.6)</td>
<td>2 (1.8)</td>
</tr>
</tbody>
</table>

Note: EF: Ejection fraction as obtained from echocardiography

Table 2b. Distribution of ejection fraction into the four quartiles of MR-proADM

<table>
<thead>
<tr>
<th>Quartile</th>
<th>EF&lt;30%</th>
<th>EF 30-40%</th>
<th>EF 31-50%</th>
<th>EF&gt;50%</th>
<th>Unclassified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1, n (%)</td>
<td>0</td>
<td>2 (1.8)</td>
<td>9 (8.3)</td>
<td>98 (89.9)</td>
<td>0</td>
</tr>
<tr>
<td>Q2, n (%)</td>
<td>2 (1.9)</td>
<td>4 (3.7)</td>
<td>10 (9.3)</td>
<td>92 (85.2)</td>
<td>0</td>
</tr>
<tr>
<td>Q3, n (%)</td>
<td>2 (1.8)</td>
<td>6 (5.4)</td>
<td>12 (10.8)</td>
<td>89 (80.2)</td>
<td>2 (1.8)</td>
</tr>
<tr>
<td>Q4, n (%)</td>
<td>2 (1.9)</td>
<td>13 (12.3)</td>
<td>20 (18.9)</td>
<td>69 (65.1)</td>
<td>2 (1.9)</td>
</tr>
</tbody>
</table>

Note: EF: Ejection fraction as obtained from echocardiography
Table 3. Effect of intervention of selenium and coenzyme Q10 on cardiovascular mortality in an elderly population having a copeptin or a mid-regional pro-adrenomedullin concentration above, or below median concentration, and applying a follow-up time of 10 years.

| Variables          | Copeptin conc below median |   | Copeptin conc above median |   | MR-proADM conc below median |   | MR-proADM conc above median |   |
|--------------------|-----------------------------|--|--|-----------------------------|--|--|-----------------------------|--|--|
|                    | Hazard ratio                | p-value | 95% confidence interval | Hazard ratio | p-value | 95% confidence interval | Hazard ratio | p-value | 95% confidence interval | Hazard ratio | p-value | 95% confidence interval |
| Age                | 1.15                        | 0.003   | 1.05-1.25                | 1.17         | <0.0001 | 1.08-1.26                | 1.17         | 0.004   | 1.05-1.29                | 1.15         | 0.0001 | 1.07-1.23                |
| Male               | 5.33                        | <0.0001 | 2.74-10.38               | 0.99         | 0.97   | 0.62-1.60                | 2.36         | 0.02    | 1.15-4.84                | 1.86         | 0.008  | 1.18-2.93                |
| Smoker             | 1.18                        | 0.79    | 0.35-3.99                | 2.02         | 0.01   | 1.15-3.57                | 1.09         | 0.89    | 0.34-3.47                | 2.08         | 0.01   | 1.17-3.70                |
| Hyperlipidemia     | 1.40                        | 0.40    | 0.64-3.04                | 1.08         | 0.80   | 0.60-1.92                | 1.62         | 0.22    | 0.75-3.49                | 0.94         | 0.84   | 0.54-1.64                |
| Diabetes           | 0.99                        | 0.97    | 0.46-2.11                | 1.38         | 0.21   | 0.84-2.28                | 1.15         | 0.75    | 0.50-2.64                | 1.39         | 0.17   | 0.87-2.21                |
| Hb<120g/L          | 1.33                        | 0.58    | 0.49-3.63                | 1.36         | 0.30   | 0.76-2.45                | 0.81         | 0.78    | 0.18-3.60                | 1.28         | 0.40   | 0.72-2.30                |
| Obstr pulm disease | 1.20                        | 0.70    | 0.49-2.94                | 1.51         | 0.20   | 0.80-2.86                | 0.76         | 0.71    | 0.17-3.28                | 1.58         | 0.11   | 0.90-2.75                |
| Hypertension       | 0.98                        | 0.96    | 0.47-2.07                | 1.36         | 0.27   | 0.79-2.34                | 1.39         | 0.39    | 0.66-2.95                | 1.10         | 0.72   | 0.64-1.89                |
| IHD                | 1.72                        | 0.14    | 0.84-3.51                | 1.17         | 0.58   | 0.68-2.03                | 1.72         | 0.17    | 0.79-3.73                | 1.15         | 0.58   | 0.70-1.89                |
| EF<40%             | 1.68                        | 0.44    | 0.46-6.15                | 0.95         | 0.90   | 0.47-1.95                | 2.47         | 0.23    | 0.56-10.91               | 0.97         | 0.93   | 0.50-1.89                |
| ACE-inhibitors     | 0.74                        | 0.48    | 0.33-1.69                | 1.21         | 0.48   | 0.72-2.04                | 0.70         | 0.54    | 0.22-2.17                | 1.12         | 0.65   | 0.69-1.80                |
| Diuretics          | 2.07                        | 0.03    | 1.09-3.92                | 1.02         | 0.94   | 0.64-1.62                | 1.11         | 0.78    | 0.53-2.31                | 1.23         | 0.38   | 0.78-1.92                |
| Selenium + Q10     | 0.39                        | 0.008   | 0.20-0.78                | 0.59         | 0.02   | 0.38-0.93                | 0.46         | 0.02    | 0.24-0.91                | 0.60         | 0.03   | 0.38-0.95                |

Note: EF: Ejection fraction; IHD: Ischemic heart disease; Q10: Coenzyme Q10
Study population  
N=443

Active intervention  
N=216

Placebo  
N=221

Mortality  
N=28

Mortality  
N=36

Drop outs  
N=71

Drop outs  
N=81

Final population active treatment at 1900 days  
N=117

Final population placebo at 1900 days  
N=104
Figure 2

Vertical bars denote 0.95 confidence intervals

Study start 18 months 48 months

4 6 8 10 12 14 16 18 20 pmol/L

Placebo
Active treatment
Figure 3a

Patients at risk

<table>
<thead>
<tr>
<th></th>
<th>Study start</th>
<th>800 days</th>
<th>1600 days</th>
<th>2400 days</th>
<th>3200 days</th>
<th>4000 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active treatment</td>
<td>111</td>
<td>106</td>
<td>96</td>
<td>79</td>
<td>62</td>
<td>15</td>
</tr>
<tr>
<td>Placebo</td>
<td>106</td>
<td>99</td>
<td>88</td>
<td>73</td>
<td>51</td>
<td>15</td>
</tr>
</tbody>
</table>
Figure 3b

Patients at risk

<table>
<thead>
<tr>
<th></th>
<th>At study start</th>
<th>800 days</th>
<th>1600 days</th>
<th>2400 days</th>
<th>3200 days</th>
<th>4000 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active treatment</td>
<td>110</td>
<td>108</td>
<td>102</td>
<td>92</td>
<td>82</td>
<td>32</td>
</tr>
<tr>
<td>Placebo</td>
<td>116</td>
<td>114</td>
<td>107</td>
<td>96</td>
<td>83</td>
<td>27</td>
</tr>
</tbody>
</table>
Figure 4

Vertical bars denote 0.95 confidence intervals

Study start 18 months 48 months

pmol/L

placebo active treatment
Figure 5a

 Patients at risk

<table>
<thead>
<tr>
<th></th>
<th>At study start</th>
<th>800 days</th>
<th>1600 days</th>
<th>2400 days</th>
<th>3200 days</th>
<th>4000 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active treatment</td>
<td>108</td>
<td>101</td>
<td>90</td>
<td>72</td>
<td>57</td>
<td>20</td>
</tr>
<tr>
<td>Placebo</td>
<td>109</td>
<td>101</td>
<td>90</td>
<td>74</td>
<td>49</td>
<td>14</td>
</tr>
</tbody>
</table>
Figure 5b

### Patients at risk

<table>
<thead>
<tr>
<th></th>
<th>At study start</th>
<th>800 days</th>
<th>1600 days</th>
<th>2400 days</th>
<th>3200 days</th>
<th>4000 days</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Active treatment</strong></td>
<td>108</td>
<td>108</td>
<td>103</td>
<td>96</td>
<td>85</td>
<td>27</td>
</tr>
<tr>
<td><strong>Placebo</strong></td>
<td>109</td>
<td>108</td>
<td>101</td>
<td>91</td>
<td>81</td>
<td>26</td>
</tr>
</tbody>
</table>